Workflow
Jinhe Biotechnology(002688)
icon
Search documents
金河生物(002688) - 关于金河生物科技股份有限公司二零二四年年度股东大会的法律意见书
2025-05-23 10:17
華聯律師事務所 年度股东大会的法律意见书 致:金河生物科技股份有限公司 根据中国证监会发布的《上市公司股东大会规则》(下称《" 股东大会规则》") 的有关规定,北京市华联律师事务所(下称"本所")接受金河生物科技股份有 限公司(下称"公司")的委托,指派赫志律师、郝丽霞律师出席公司 2024 年 年度股东大会(下称"本次股东大会"),并就本次股东大会的召集和召开程序、 召集人资格、出席会议人员资格、会议的表决程序及表决结果等事宜发表法律意 见。 本所及经办律师依据《中华人民共和国证券法》(以下简称《证券法》)《律 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则(试 行)》等规定及本法律意见书出具日以前已经发生或者存在的事实,严格履行了 法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证本法 律意见所认定的事实真实、准确、完整,所发表的结论性意见合法、准确,不存 在虚假记载、误导性陈述或者重大遗漏,并承担相应法律责任。 一、本次股东大会的召集和召开程序 本次股东大会由公司董事会根据 2025 年 4 月 25 日召开的第六届董事会第 二十五次会议召集;公司董事会于 2025 ...
金河生物: 关于控股股东部分股份解除质押的公告
Zheng Quan Zhi Xing· 2025-05-22 08:17
证券代码:002688 证券简称:金河生物 公 告编号:2025-042 一、股东股份解除质押基本情况 | | 是否为控股股东 | | 本次解除 | | 占其所 | | | 占公司 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 质押开始 | | | | | 质押解除 | | 日 | | | | | | | | | | | | | | 股东名称 | 或第一大股东及 | | 质押股份 | | | 持股份 | | | 总股 | | | | | 本 | | | 质权人 | | | | | | | | | | | | | | | | | | 日期 | | | | | 期 | | | 其一致行动人 | | 数量 | | 比例 | | 比例 | | | | | | | 金河控股 | 是 | | 22,800,000 | | 9.43% | | 2.95% | | | | | | | | | | | | | | 月 30 | | 日 | | 21 | | | 日 ...
金河生物(002688) - 关于控股股东部分股份解除质押的公告
2025-05-22 08:00
证券代码:002688 证券简称:金河生物 公告编号:2025-042 金河生物科技股份有限公司(以下简称"公司")于近日收到控股股东内蒙 古金河控股有限公司(以下简称"金河控股")的通知,获悉金河控股所持有本 公司的部分股份解除质押。具体事项如下: 一、股东股份解除质押基本情况 | 股东名称 | 是否为控股股东 | 本次解除 | 占其所 | 占公司 | 质押开始 | | 质押解除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 或第一大股东及 | 质押股份 | 持股份 | 总股本 | 日期 | | 期 | | | | 其一致行动人 | 数量 | 比例 | 比例 | | | | | | 金河控股 | 是 | 22,800,000 | 9.43% | 2.95% | 2023 年 10 | 2025 | 年 5 月 | 广发证券股 | | | | | | | 月 30 日 | 21 | 日 | 份有限公司 | | 合计 | — | 22,800,000 | 9.43% | 2.95% | — | | — | — | 1、本 ...
金河生物:控股股东解除2280万股质押股份
news flash· 2025-05-22 08:00
Core Viewpoint - Jinhe Biological (002688) announced the release of 22.8 million pledged shares by its controlling shareholder, Jinhe Holdings, which represents 9.43% of its holdings and 2.95% of the company's total share capital [1] Group 1 - The pledged shares were initially pledged on October 30, 2023, and the release date is set for May 21, 2025 [1] - The pledgee for these shares is GF Securities Co., Ltd [1] - As of the announcement date, Jinhe Holdings and its concerted parties have a total of 140 million pledged shares, accounting for 50.31% of their holdings, indicating no risk of forced liquidation [1]
代糖概念午后走低 保龄宝逼近跌停
news flash· 2025-05-22 05:22
Group 1 - The sugar substitute concept is experiencing a decline in the afternoon trading session, with Baolingbao (002286) nearing a trading halt [1] - Other companies in the sector, including Sanyuan Bio (301206), Jinhai Bio (002688), Vinegar Chemical (603968), and Xinghuo Technology (600866), are also seeing a drop in stock prices [1] - There is an influx of dark pool funds entering these stocks, indicating potential interest from institutional investors [1]
动物疫苗概念上涨4.00%,6股主力资金净流入超千万元
Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].
金河生物控股股东拟减持 2021年定增募资8.2亿元
Zhong Guo Jing Ji Wang· 2025-05-19 07:47
Group 1 - The controlling shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., plans to reduce its stake in Jinhai Biological by up to 22,563,389 shares, representing no more than 3% of the total share capital [1] - The reduction will occur within three months from June 10, 2025, to September 9, 2025, through centralized bidding and block trading [1] - The reason for the share reduction is to repay pledged debts, with shares originating from a previous restructuring and capital increases [1] Group 2 - In a previous non-public offering on August 10, 2021, Jinhai Biological issued 145,132,743 shares at a price of 5.65 yuan per share, raising approximately 820 million yuan [2] - After deducting issuance costs, the net funds raised amounted to approximately 802 million yuan, with 145 million yuan allocated to share capital and over 657 million yuan to capital reserves [2]
周末要闻回顾:证监会重磅发布!上市公司重大资产重组新规来了
news flash· 2025-05-18 06:51
Group 1 - The Ministry of Commerce has issued the third batch of best practice cases for the national service industry expansion pilot, focusing on replicable and promotable experiences for service industry development [1] - The best practices include 11 innovative measures across three areas: industrial ecosystem construction, international cooperation, and regional collaboration [1] - The measures reflect collaborative openness and integrated innovation in key industries such as culture, technology, and healthcare [1] Group 2 - The State Administration for Market Regulation is soliciting public opinions on the revised draft regulations to curb the abuse of administrative power that restricts competition [2] - The National Bureau of Statistics reported that the average annual salary for urban non-private and private sector employees in 2024 will be CNY 124,110 and CNY 69,476, respectively [2] Group 3 - The Ministry of Finance and the Financial Regulatory Bureau have announced a push for the digitalization of bank confirmations to enhance efficiency and security [3] - The notification emphasizes the importance of increasing the number of entities accessing the bank confirmation platform [3] Group 4 - The Ministry of Commerce and the National Development and Reform Commission have revised the "Catering Industry Promotion and Management Measures," adding provisions to encourage international cooperation and digital development [4] - The revised measures include 25 articles aimed at promoting high-quality development in the catering industry [4] Group 5 - The State-owned Assets Supervision and Administration Commission announced personnel changes in 10 central enterprises, including leadership appointments and removals [5][6] Group 6 - The China Securities Regulatory Commission encourages private equity funds to participate in mergers and acquisitions of listed companies, with adjustments to lock-up periods for investments [7] - The Shenzhen Stock Exchange is monitoring stocks with abnormal price fluctuations, including "ST Yushun" and "ST Jiajia" [8] Group 7 - The Shenzhen Stock Exchange will host the 2025 Global Investor Conference to showcase the investment value of Chinese assets and the A-share market [9] Group 8 - The Ministry of Industry and Information Technology is accelerating the development of 5G-A and 6G technologies to support modern industrial systems [13] - The National Data Bureau aims for the core value added of the digital economy to exceed 10% of GDP by the end of 2025 [14] Group 9 - The Ministry of Industry and Information Technology reported that China has built the world's largest and most advanced information and communication network, with 5G applications covering 86 of 97 national economic categories [15] Group 10 - Binhai Energy plans to acquire 100% equity of Cangzhou Xuyang Chemical Co., Ltd., with the stock expected to resume trading on May 19, 2025 [17] - The automotive industry is set to benefit from a significant release of funds due to a recent reserve requirement ratio cut, potentially exceeding CNY 1 trillion [18] Group 11 - Xiaomi's President revealed that products using the self-developed "Xuanjie" chip will extend beyond smartphones [21] - Huamin Co. and Tiantai Robotics signed a strategic cooperation agreement to advance the robotics industry [21] Group 12 - Xiangzi High-Tech announced the sale of an 80% stake in Heilongjiang Yunfeng Automobile Co., Ltd. for CNY 24.6 million, aiming to restructure its fuel vehicle business [22] - ST Kexin has successfully removed its delisting risk warning and will change its stock name to Kexin Development [23] Group 13 - *ST Aonong has received approval to remove its delisting risk warning, with its stock name changing to Aonong Biological [24][25] - Jianghan New Materials plans to repurchase shares worth CNY 200 million to CNY 400 million [26] Group 14 - Siyuan Electric intends to repurchase shares worth CNY 300 million to CNY 500 million [27] - Liren Lizhuang reported that products containing "Mikang Sulfur" have a minimal impact on overall business performance [28] Group 15 - Jinhe Biological's controlling shareholder plans to reduce its stake by up to 3% [29] - Guanghui Energy announced the transfer of 15.03% of its shares to two insurance companies [30] Group 16 - Tailing Microelectronics reported a reduction in the National Big Fund's shareholding to 6.95% [31] - AVIC High-Tech plans to invest CNY 918 million to enhance its capabilities in aviation composite materials [32]
金河生物(002688) - 关于控股股东减持股份预披露的公告
2025-05-16 12:32
关于控股股东减持股份预披露的公告 控股股东内蒙古金河控股有限公司保证向本公司提供的信息内容真实、准确、 完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示: 金河生物科技股份有限公司(以下简称"公司")控股股东内蒙古金河控股 有限公司(以下简称"金河控股")持有本公司股份 241,758,670 股,占本公司 总股本的 32.14%(总股本按剔除公司回购专用账户中的股份数量 19,521,410 股 计算,下同),计划在本减持计划公告之日起 15 个交易日后的 3 个月内(即 2025 年 6 月 10 日至 2025 年 9 月 9 日)通过集中竞价交易、大宗交易方式减持公司股 份合计不超过 22,563,389 股,即不超过公司总股本的 3%,其中,拟以集中竞价 方式减持公司股份不超过 7,521,130 股(占总股本比例 1%),以大宗交易方式 减持公司股份不超过 15,042,259 股(占总股本比例 2%)。 证券代码:002688 证券简称:金河生物 公告编号:2025-041 金河生物科技股份有限公司 公司于近期收到控股股东金 ...
金河生物:金河控股拟减持不超3%公司股份
news flash· 2025-05-16 12:29
金河生物(002688)公告,控股股东金河控股计划在2025年6月10日至2025年9月9日期间,通过集中竞 价交易和大宗交易方式减持公司股份不超过2256.34万股,即不超过公司总股本的3%。其中,通过集中 竞价方式减持不超过752.11万股,占总股本比例1%;通过大宗交易方式减持不超过1504.23万股,占总 股本比例2%。减持原因是偿还质押债务,减持价格将根据市场价格确定。 ...